Related Experiment Video
Updated: Feb 5, 2026

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Emerging drugs for irritable bowel syndrome
Sylvie Bradesi1, Kirsten Tillisch, Emeran Mayer
1Center for Neurovisceral Sciences & Women's Health, CURE: Digestive Diseases Research Center, UCLA Division of Digestive Diseases, GLA VA HC Bldg., 115/CURE, 11301 Wilshire Blvd., Los Angeles, California 90073, USA.
Irritable bowel syndrome (IBS) remains poorly understood, with current treatments offering limited relief. New drug targets along the brain-gut axis show promise for improved IBS symptom management.
Area of Science:
- Gastroenterology
- Neurogastroenterology
- Pharmacology
Background:
- Irritable bowel syndrome (IBS) is a prevalent chronic gastrointestinal disorder.
- Current understanding of IBS pathophysiology is incomplete.
- Existing pharmacological treatments provide unsatisfactory global symptom relief and patient satisfaction.
Purpose of the Study:
- To review the current state of IBS pathophysiology.
- To highlight novel therapeutic targets within the brain-gut axis.
- To discuss advancements in clinical trial design for evaluating new IBS candidate drugs.
Main Methods:
- Literature review of recent research on IBS pathophysiology.
- Analysis of emerging drug targets in the brain-gut axis.
- Discussion of innovative clinical trial methodologies for IBS patient populations.
Main Results:
- The pathophysiology of IBS is complex and involves the brain-gut axis.
- Several novel drug candidates targeting different aspects of IBS pathophysiology are under development.
- Improved clinical trial designs are crucial for accurate evaluation of these new therapies.
Conclusions:
- Despite advances, IBS pathophysiology requires further elucidation.
- Novel therapeutic strategies targeting the brain-gut axis offer potential for improved IBS treatment.
- Refined clinical trial approaches are essential to validate the efficacy of new IBS medications.
Related Concept Videos
Introduction Cardiac Emergencies
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome III: Medical and Nursing Management
Emerging Adulthood
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...

